Rizatriptan

Overview

Rizatriptan, sold under the brand name Maxalt among others, is a medication used for the treatment of migraine headaches. It is taken by mouth. It can also be applied on the tongue. It is a serotonin (5-HT) 1B/1D receptor agonist (triptan).[1][2][3] WP

Common side effects include chest pain, dizziness, dry mouth, and tingling. Other side effects may include myocardial infarction, stroke, high blood pressure, serotonin syndrome, and anaphylaxis. Excessive use may result in medication overuse headaches. Use is not recommended during pregnancy and breastfeeding is not recommended within 24 hours after taking a dose. Rizatriptan is in the triptan class and is believed to work by activating the 5-HT₁ receptor.[2][4] WP

Rizatriptan was patented in 1991 and came into medical use in 1998. It is available as a generic medication. In 2023, it was the 208th most commonly prescribed medication in the United States, with more than 2 million prescriptions. Rizatriptan is available in combination with meloxicam as meloxicam/rizatriptan.[4–8] WP

Uses, dosage and effects

Medical uses

Rizatriptan is indicated to treat acute migraine attacks with or without aura. It does not prevent future migraine attacks. A 2010 review found rizatriptan to be more efficacious and tolerable than sumatriptan.[1][3][9][10] WP

Risks and side effects

Contraindications

Rizatriptan and other triptans can cause vasoconstriction, they are contraindicated in people with cardiovascular conditions.[11] WP

Adverse effects

Frequent adverse effects (incidence less than 10%) are dizziness, drowsiness, asthenia/fatigue, and nausea. Clinical adverse experiences were typically mild and short-lasting (2–3 hours).[11] WP

Interactions

Interactions

Rizatriptan has an important but complex interaction with a metabolite of the beta blocker propranolol. This interaction involves the enzyme monoamine oxidase A (MAO-A). Due to the interaction, the dose of rizatriptan should be reduced to 5 mg when it is combined with propranolol.[12] WP

Pharmacology

Mechanism of action

Rizatriptan acts as an agonist at serotonin 5-HT1B and 5-HT1D receptors. Like the other triptans sumatriptan and zolmitriptan, rizatriptan induces vasoconstriction—possibly by inhibiting the release of calcitonin gene-related peptide from sensory neurons in the trigeminal nerve.[13] WP

History

History

Rizatriptan was patented in 1991 and was introduced for medical use in 1998.[5][6] WP

Legal status

Brand names

Brand names include Rizalt, Rizalt RPD, Rizact (India), Rizafilm, Maxalt, and Maxalt-MLT.[1][3][14][15][16] WP

Chemistry

Formula

C15H19N5 PC

CAS number

144034-80-0 PC

Molar mass (g/mol)

269.34 PC

IUPAC name (computed by PubChem)

N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine PC

SMILES

CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3 PC

InChIKey

ULFRLSNUDGIQQP-UHFFFAOYSA-N PC

PubChem CID

5078

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Maxalt- rizatriptan benzoate tablet; Maxalt-MLT- rizatriptan benzoate tablet, orally disintegrating. 1 June 2022
2. Other Rizatriptan Benzoate Monograph for Professionals
3. Journal / agency Archived copy
4. Other British National Formulary: BNF 76. 2018
5. Journal / agency Drug Approval Package: Maxalt/Rizatritan Benzoate NDA# 20864 & 20865. 30 March 2001
6. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
7. Other The Top 300 of 2023
8. Other Rizatriptan Drug Usage Statistics, United States, 2014 - 2023
9. Journal / agency Rizatriptan
10. Journal / agency Göbel H. Efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based analysis. Expert Rev Neurother. 2010. doi:10.1586/ern.10.24 · PMID 20367203
11. Journal / agency Hargreaves RJ, Lines CR, Rapoport AM, Ho TW, Sheftell FD. Ten years of rizatriptan: from development to clinical science and future directions. Headache. 2009. doi:10.1111/j.1526-4610.2008.01335.x · PMID 19161563
12. Journal / agency Millson DS, Tepper SJ, Rapoport AM. Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opinion on Pharmacotherapy. March 2000. doi:10.1517/14656566.1.3.391 · PMID 11249525
13. Journal / agency Wellington K, Plosker GL. Rizatriptan: an update of its use in the management of migraine. Drugs. 2002. doi:10.2165/00003495-200262100-00007 · PMID 12093318
14. Other Rishum01_5_982075622.pdf
15. Other Maxalt Oral: Uses, Side Effects, Interactions, Pictures, Warnings & More
16. Other Rizact 10 mg Tablet - Uses, Dosage, Side Effects, Composition

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.